Boehringer Ingelheim

Top-Feature

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Oracle Germany
PP Consulting
Photo
CHEManager International c/o Wiley-VCH GmbH
LISA Life Science Austria
SchüllerConsulting
GlobalData
Photo
Boehringer Ingelheim
Photo
Bayer AG
Frost & Sullivan
Thomson Reuters
Photo
JMP Statistical Discovery / SAS Institute GmbH
Photo
BearingPoint GmbH
Photo
DCAT - Drug, Chemical & Associated Technologies Association
Photo
C² PHARMA
QUANTRO Therapeutics GmbH
Photo
ACIB Austrian Centre of Industrial Biotechnology